Previous Article | Next Article 
Journal of Virology, June 2000, p. 5495-5501, Vol. 74, No. 12
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Gamma Interferon Is Not Required for Mucosal
Cytotoxic T-Lymphocyte Responses or Heterosubtypic Immunity to
Influenza A Virus Infection in Mice
Huan H.
Nguyen,*
Frederik W.
van Ginkel,
Huong L.
Vu,
Miroslav J.
Novak,
Jerry
R.
McGhee, and
Jiri
Mestecky
Department of Microbiology and The
Immunobiology Vaccine Center, University of Alabama at Birmingham,
Birmingham, Alabama 35294-2170
Received 29 September 1999/Accepted 18 March 2000
 |
ABSTRACT |
Heterosubtypic immunity (HSI) is defined as cross-protection
against influenza virus of a different serotype than the virus initially encountered and is thought to be mediated by influenza virus-specific cytotoxic T lymphocytes (CTL). Since gamma interferon (IFN-
) stimulates cytotoxic cells, including antigen-specific CTL
which may control virus replication by secretion of antiviral cytokines
such as tumor necrosis factor alpha and IFN-
, we have investigated
the mechanism of HSI by analyzing the role of IFN-
for HSI in
IFN-
gene-deleted (IFN-
/
) mice. It has been
reported that IFN-
is not required for recovery from primary
infection with influenza virus but is important for HSI. Here, we
conclusively show that IFN-
is not required for induction of
secondary influenza virus-specific CTL responses in mediastinal lymph
nodes and HSI to lethal influenza A virus infection. Although T helper
2 (Th2)-type cytokines were upregulated in the lungs of
IFN-
/
mice after virus challenge, either Th1- or
Th2-biased responses could provide heterosubtypic protection.
Furthermore, titers of serum-neutralizing and cross-reactive antibodies
to conserved nucleoprotein in IFN-
/
mice did not
differ significantly from those in immunocompetent mice. These results
indicate that lack of IFN-
does not impair cross-reactive
virus-specific immune responses and HSI to lethal infection with
influenza virus. Our findings provide new insight for the mechanisms of
HSI and should be valuable in the development of protective mucosal
vaccines against variant virus strains, such as influenza and human
immunodeficiency virus.
 |
INTRODUCTION |
Protection against challenge with
influenza viruses of the same strain is normally attributed to
neutralizing antibodies specific for two viral membrane glycoproteins,
hemagglutinin and neuraminidase. Due to periodic antigenic shifts in
these two glycoproteins, virus-neutralizing antibodies induced by
primary infection fail to protect from secondary infection with a
different subtype, and cross-protection between different subtypes of
influenza A virus is mediated by heterosubtypic immunity (HSI)
(30). Although the precise effector mechanisms for HSI
remain undefined, HSI is thought to be mediated by subtype cross-reactive cytotoxic T lymphocytes (CTL) (34, 36, 41, 47). These CTL recognize conserved epitopes of internal proteins, such as nucleoprotein (NP) or matrix protein shared by influenza A
virus subtypes. Passive transfer of large numbers of in vitro-activated T cells possessing subtype-specific cytotoxic activity to influenza virus-infected mice can reduce pulmonary influenza virus titers, promote their recovery, and provide protection against infection under
certain circumstances (6, 18, 20, 33, 39, 44, 45). More
recently, we have reported that antigen-specific CTL responses induced
in mediastinal lymph nodes (MLN), a type of mucosa-associated lymphoid
tissue (MALT), are associated with host recovery from lethal infection
with heterosubtypic influenza A virus (25). The CTL
responses may control virus infection through direct lysis of infected
cells or by secretion of antiviral cytokines such as gamma interferon
(IFN-
) and tumor necrosis factor alpha (TNF-
) (for a review, see
reference 13). While the direct lysis of
virus-infected cells by CTL is thought to control infection with
noncytopathic virus, secretion of antiviral cytokines by CTL is
considered more effective in control of infection by cytopathic viruses
such as influenza virus.
IFN-
exerts pleiotropic effects, including direct antiviral activity
and stimulation of antiviral immune responses. In virally infected
cells, IFN-
induces synthesis of proteins and enzymes that inhibit
viral replication by impairing accumulation of virus-specific mRNA,
double-stranded RNA, and proteins (26). In addition, IFN-
stimulates antiviral immune responses by upregulating major
histocompatibility complex (MHC) molecules on antigen-presenting cells
(4), augmenting the proteolysis and peptide transport
machinery in antigen-presenting cells (28, 42), and
activating immune cells (5, 21). IFN-
plays a protective
role against infections by vaccinia (12, 15), herpes simplex
(32), cytomegalovirus (11), murine hepatitis virus 3 (19), lymphocytic choriomeningitis virus
(16), and adenovirus (43). Interestingly, IFN-
is not necessary for recovery from primary infection with influenza
virus (7) but has been reported to play a role in HSI
(1). However, the latter study employed immunization as well
as challenge protocols distinct from those routinely used for studies
of HSI (3, 17, 25, 30, 46). Thus, the precise role of
IFN-
in HSI has not been unambiguously elucidated.
Antigen-specific MHC class I-restricted CTL secrete IFN-
upon
antigenic stimulation (14, 22), and differentiation to CTL
effector cells is dependent on the action of IFN-
(21, 31). The mutual interaction between antigen-specific CTL
responses and IFN-
and the association of CTL responses in HSI led
us to assess this in mice deficient in IFN-
. In this report, the
effect of IFN-
on induction of cellular and humoral immune responses and HSI to lethal influenza challenge was systematically studied using
IFN-
gene-deleted (IFN-
/
) mice.
 |
MATERIALS AND METHODS |
Viruses.
Influenza virus strains A/Udorn/307/72 (H3N2)
(henceforth A/Udorn) (a gift from Brian Murphy, National
Institutes of Health, Bethesda, Md.) and A/PR/8/34 (H1N1) (a gift from
Thomas M. Moran, Mount Sinai School of Medicine, New York, N.Y.) were
prepared as previously reported (25). Mouse-adapted virus
A/PR/8/34 (H1N1), prepared as lung homogenates of intranasally infected
mice, was used for a challenge.
Mice.
Six-week-old female BALB/c
(H-2d) and C57BL/6 (H-2b)
(wild-type [WT]) mice and mice homozygous for a targeted disruption
of the IFN-
gene (C57BL/6 IFN-
/
mice) were
purchased from Jackson Laboratories (Bar Harbor, Maine). The BALB/c
IFN-
/
mice were generously provided by Timothy A. Stewart of Genentech (San Francisco, Calif.). All mice were maintained
under pathogen-free conditions in a flexible Trexler isolator and
provided sterile food and water ad libitum. The mice used in our
experiments were between 8 and 10 weeks of age.
Immunizations and challenge of mice with influenza virus.
All mice were immunized with 5 × 105 PFU of virus.
Ketamine-anesthetized mice each received 50 µl of virus inoculum for
total respiratory tract (TRT) infection. For intravenous (i.v.)
immunization, 200 µl of virus suspension was injected into the tail
vein of each mouse. Immunization by TRT and i.v. methods resulted in
100 and 98% of mice displaying antibody responses, respectively. The same pattern was observed in immunocompetent as well as in
IFN-
/
mice. The absence of antibody (Ab) response in
2% of i.v.-immunized mice reflects occasional unsuccessful i.v.
immunization. For the study of HSI, all mice must be successfully
immunized (monitored by Ab response) with serotypes different from that
used for challenge. Therefore, before virus challenge all mice were
tested for the presence of virus-specific serum Ab by enzyme-linked
immunosorbent assay (ELISA) to ensure that immune responses to the
initial virus infection had been induced. Mice without virus-specific
Abs were excluded from these experiments. For virus challenges,
ketamine-anesthetized mice were infected by the TRT method with 250 PFU
(5× the 50% lethal dose) resuspended in 50 µl of phosphate-buffered
saline (PBS) per ml per mouse.
Cells.
EL-4 (H-2b) T-cell lymphoma
and P815 (H-2d) mastocytoma cells (American Type
Culture Collection, Rockville, Md.) were maintained in standard
complete medium (RPMI 1640; Gibco, Grand Island, N.Y.) containing 10%
fetal bovine serum (FBS) and antibiotics. Hybridoma 3.155 cells (ATCC)
secrete a rat monoclonal immunoglobulin M (IgM) Ab specific for all
mouse Lyt-2 (CD8) alleles. These Abs can inhibit T-cell-mediated cytolysis in the absence of complement (29).
Lung tissue extracts for cytokine analysis.
Lung tissue
extracts were prepared as described by others (9). Intact
lungs were collected for assessment of cytokines characteristic of Th1-
or Th2-type responses. Prior to lung removal, the pulmonary vasculature
was perfused with 1 ml of PBS containing 5 mM of EDTA via the right
ventricle. After removal, whole lungs were homogenized in 3 ml of lysis
buffer containing 0.5% Triton X-100, 150 mM Tris, 1 mM
CaCl2, and 1 mM MgCl2 (pH 7.4), using a tissue
homogenizer (Biospec Products, Inc., Racine, Wis.). Homogenates were
incubated on ice for 30 min and then centrifuged at 1,000 × g for 10 min. Supernatants were collected after passage through a
0.45-µm-pore-size filter and stored at
20°C until assessed for cytokines.
Analysis of IFN-
mRNA.
Whole lungs were homogenized, and
total RNA was isolated by phenol-chloroform extraction with RNA STAT-60
reagent (Tel-test, Inc., Friendswood, Tex.). All reverse transcription
and PCRs were performed with reagents from the GeneAmp RNA PCR Kit
(Perkin-Elmer, Foster City, Calif.) according to the producer's
protocols. Murine IFN-
cDNA was amplified using
5'-TGAACGCTACACACTGCATCTTGG-3' as a sense primer and
5'-CGACTCCTTTTCCGCTTCCTGAG-3' as an antisense primer
(8). PCR products were visualized by ethidium
bromide-stained gels.
Virus neutralization assay.
Virus neutralization (VN)
activity was assayed as previously reported (25). Briefly,
heat-inactivated (30 min at 56°C) serum samples were serially diluted
in 96-well tissue culture plates (Costar, Cambridge, Mass.) at 4 wells
per dilution, starting at a 1:8 dilution in a total volume of 50 µl
of RPMI 1640 medium without serum. Influenza virus (A/Udorn or
A/PR/8/34) at a 50% tissue culture infective dose of 200 in 50 µl of
RPMI 1640 medium was added to each well. Control wells contained either
medium only instead of immune serum or medium only without virus. After incubation at room temperature for 1 h, 50 µl of RPMI 1640 medium containing 3.75 µg of trypsin per ml was added to each well
and transferred into wells with an 80% monolayer of MDCK cells
previously washed with PBS. The plates were incubated at 35°C in a
5% CO2 atmosphere. Three days later, 100 µl of 10%
formalin was added, plates were incubated for 1 h, and cells were
washed with PBS and stained with Coomassie brilliant blue for the
cytopathic effect determination. VN titer was calculated as an average
of 4 dilutions per serum sample at which 100% VN occurred.
ELISA.
The assay was performed as previously described
(25). Briefly, 96-well MaxiSorp Nunc-Immuno plates (Nalge
Nunc International, Naperville, Ill.) were coated with RNP of influenza
A virus at a concentration of 0.5 µg/ml. The bound Ab was detected
with enzyme-conjugated anti-mouse Ig (Southern Biotechnology
Associates, Birmingham, Ala.). IgG1 and IgG2a subclass titers were
determined using enzyme-conjugated monoclonal anti-mouse IgG1 (G1 7.3;
2 µg/ml), IgG2a (R19-15; 1 µg/ml) heavy-chain-specific Abs
(PharMingen, San Diego, Calif.), respectively.
Cytokine ELISA assays.
Cytokine levels in lung extracts and
culture supernatants were determined by an ELISA with capture and
detection monoclonal Abs (PharMingen) specific for the murine cytokines
interleukin-4 (IL-4) and IFN-
. The cytokine ELISA assays were
performed as previously described (38). To determine the
amount of cytokine present in test samples, twofold dilutions of
recombinant murine IL-4 (Endogen, Boston, Mass.) and IFN-
(Genzyme
Corp., Cambridge, Mass.) were used as standard curves, and values for
the test samples were then interpolated. The actual values represent
the mean of triplicate samples ± 1 standard deviation. The
detection limits were 25 and 20 pg/ml for IFN-
and IL-4, respectively.
Generation of antigen-specific CTL effector cells.
Stimulation of antigen-specific CTL effector cells was performed as
previously described (25). Briefly, spleens and MLN were
taken from five mice per experimental group, and single-cell suspensions were pooled for further analysis. A portion of the spleen
cell suspension, stimulator cells, was infected with influenza virus
A/Udorn at a multiplicity of infection (MOI) of 2 to 4 or with
A/PR/8/34 at an MOI of 4 to 6 in 0.2 ml of PBS or RPMI 1640 medium
without FBS. After incubation for 30 min at 37°C and with 5%
CO2, RPMI 1640 containing 10% FBS, 10 mM HEPES, 100 U of
penicillin per ml, 100 µg of streptomycin per ml, 0.03% glutamine,
and 3× 10
5 M 2-mercaptoethanol (complete medium) was
added, and the cell suspension was incubated for 3 h, irradiated
(3,000 R), washed, and mixed with the remaining splenocytes (responder
cells (R), at an R-to-stimulator-cell ratio of 2:1 (3 × 106 to 4 × 106 R/ml) in CTL complete
medium. Murine recombinant IL-2 (rIL-2) (R & D Systems, Inc.,
Minneapolis, Minn.) was added to cultures at day 3 (20 U/ml), followed
by an additional 3-day incubation at 37°C with 5% CO2,
after which effector cells were washed and tested with virus-infected
MHC-matched target cells in a 51Cr release assay.
Preparation of target cells.
P815
(H-2d) and EL-4 (H-2b)
cells were infected at an MOI of 5 with A/Udorn or A/PR/8/34 influenza
virus in 100 µl of incomplete medium (without serum) for 20 min at
37°C. The cells were washed to remove unbound virus and were cultured
for 2 h in 500 µl of complete medium containing 100 µCi of
51Cr per 106 cells. Prior to assessing
cytotoxic activity, 51Cr-labeled cells were washed three
times. The cells were counted and then used as target cells in the
cytotoxic assay, as described below.
Cytotoxicity assay.
The 51Cr-labeled P815 or
EL-4 target cells were washed three times and resuspended in complete
medium at 105 cells/ml; 100-µl aliquots of the cell
suspension were added to 96-well, round-bottom microtiter plates
containing triplicate 100-µl samples of serially diluted effector
cells. The microtiter plates were centrifuged at 400 × g for 5 min and then incubated for 4 h at 37°C and 5%
CO2. The level of released radioactivity in 100 µl of
supernatant from each well was measured in a gamma counter (Cobra II
Auto-Gamma; Packard Instrument Co., Downers Grove, Ill.). Specific
lysis was calculated from the 51Cr released in counts per
minute with the formula: percentage of specific lysis = [(experimental cpm
spontaneous cpm)/(maximal release cpm
spontaneous cpm)] × 100. The value of 51Cr, as counts
per minute for spontaneous and maximal release, was determined by
incubating target cells with either 100 µl of medium or 100 µl of
5% Triton X-100, respectively. Spontaneous release of 51Cr
in the absence of effector cells was usually less than 15%; standard
errors of the mean (SEM) were less than 5% of the mean value and are
not included.
Statistics.
The data are expressed as the mean ± 1 SEM
and compared using a two-tailed student's t test and
one-way analysis of variance. The results were analyzed using the
InStat 2.00 statistical program (GraphPad Software, San Diego, Calif.)
for Macintosh computers and were considered to be statistically
significant if P values were less than 0.05.
 |
RESULTS |
Protection of IFN-
/
mice against
challenge with mouse-adapted heterosubtypic influenza virus.
To
determine the role of IFN-
for heterosubtypic protection,
IFN-
/
mice were immunized by TRT exposure to a
sublethal dose of live A/Udorn (H3N2) virus. Four weeks later, the mice
were challenged with a lethal dose of A/PR/8/34 (H1N1) virus. Ninety
percent of IFN-
/
mice immunized previously via the
TRT method with live A/Udorn virus survived the challenge (Fig.
1b). This survival rate is comparable to
that seen in immunocompetent mice immunized previously via the TRT
method (100%) (Fig. 1a). A much lower survival rate was observed in
IFN-
/
and immunocompetent mice immunized i.v. (10 to
20%, respectively). As negative controls, unimmunized mice were
challenged with virus and exhibited 100% mortality.
IFN-
/
mice previously immunized i.v. with homologous
but not heterosubtypic serotype virus were protected from TRT challenge
with a lethal dose. No weight loss was seen in this group (Fig. 1d),
and protection from secondary infection was presumably mediated by
preexisting Ab specific for homologous outer membrane glycoproteins. A
transient weight loss was observed in both immunocompetent and
IFN-
/
mice immunized via the TRT method (Fig. 1c and
d). During the first week after challenge, the i.v. immunized and
unimmunized mice showed severe weight loss from day 2 to 6, when
mortality was first observed. These results clearly demonstrate that
IFN-
/
mice, like immunocompetent mice, developed
complete HSI against lethal infection with influenza virus. A similar
pattern of host recovery as a result of HSI was observed in both
genetically distinct C57BL/6 and BALB/c strains of WT and
IFN-
/
mice (Fig. 1). This indicates that both
H-2b and H-2d MHC
haplotypes are permissive with regard to infection, disease, and
mortality.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 1.
HSI in IFN- / mice.
IFN- / and WT mice were immunized with influenza
virus A/Udorn (H3N2) by different routes, as indicated. Four weeks
later, they were challenged with heterologous mouse-adapted influenza
strain A/PR/8/34 (H1N1) via the TRT route. The mortality rate was
monitored daily for at least 3 weeks (a and b), and body weight of
surviving individual mice was measured every 2 days until all live
animals regained their initial weight (c and d). Values are the mean of
10 mice per group.
|
|
Induction of subtype cross-reactive CTL responses in
IFN-
/
mice.
Since HSI is associated with
virus-specific CD8+ CTL induced in MALT (25),
the role of IFN-
for induction of CTL responses was examined.
Immunocompetent and IFN-
/
mice were immunized by TRT
exposure to live A/Udorn virus. Four weeks later, the mice were
challenged with a lethal dose of A/PR/8/34 (H1N1) virus. On day 3 after
challenge, five mice from each subgroup were analyzed. Lymphocytes
isolated from spleens and MLN were subjected to 6-day in vitro culture
to generate antigen-specific CTL effector cells. All groups of
immunized mice had strong heterosubtypic CTL activity against H1N1
(Fig. 2a) as well as H3N2 (data not shown) virus-infected target cells in the spleens. In contrast, when
lymphocytes isolated from MLN, the draining lymph nodes of the lungs,
were stimulated in vitro and assayed for CTL activity, positive
heterosubtypic CTL activity was detected only in MLN of mice immunized
via the TRT method. The CTL activities are similar in both
immunocompetent and IFN-
/
mice (Fig. 2b). When the
effector cells were treated with monoclonal Ab specific for the CD8
molecule before performing the cytotoxic assay, no antigen-specific
lysis was detected (Fig. 3). These results indicated that heterosubtypic virus-specific CTL activity induced in MLN is mediated predominantly by CD8+ T cells.
The data demonstrate that lack of IFN-
does not impair induction and
differentiation of virus-specific CD8+ CTL responses,
observed in different lymphoid organs following nasal or parental
routes of immunization. Furthermore, virus-specific CD8+
CTL responses induced in MLN of both WT and IFN-
/
mice were associated with HSI.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
CTL responses induced in different lymphoid organs of
BALB/c IFN- / and WT mice following immunization by
different routes. Mice were infected with a sublethal dose of strain
A/Udorn (H3N2). Four weeks later, the mice were challenged with a
lethal dose of A/PR/8/34 (H1N1) virus. On day 3 after the challenge,
five mice from each group were sacrificed. Lymphocytes were isolated
from different lymphoid organs and stimulated in vitro. After 6-day in
vitro stimulation, the cells were assayed for CTL activity against H1N1
virus-infected P815 target cells. Specific CTL activities were
determined by subtracting the nonspecific cytotoxic activity against
mock-infected P815 target cells from cytotoxic activity against
virus-infected P815 target cells. The data represent results from two
independent experiments of five mice per group.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Heterosubtypic CTL responses in MLN are mediated by
CD8+ antigen-specific CTL effector cells. Pretreatment of
CTL effector cells with monoclonal Ab specific for CD8 inhibits
antigen-specific CTL activity (see the legend to Fig. 2 for details).
|
|
Cytokine responses in the absence of IFN-
.
Since pneumonia
is the cause of death after influenza virus infection, the regulation
of immune responses at the site of infection may be essential for
recovery from viral infection and the disease. Lung extracts from
IFN-
/
and immunocompetent mice were analyzed after
the challenge for Th1- and Th2-type cytokine production. To ensure that
IFN-
/
did not produce IFN-
, lung homogenates were
analyzed for expression of mRNA specific for IFN-
, and no
IFN-
-mRNA was detected in the lung homogenates of
IFN-
/
mice (data not shown). The amount of IFN-
varied among different groups of immunocompetent mice, but
significantly elevated production of IFN-
was observed in lung
homogenates of heterosubtypically immune mice previously immunized by
the TRT route (Fig. 4). In the absence of
IFN-
, the production of Th2-type cytokines (IL-4, IL-5, and IL-6)
was significantly increased. However, there was no statistical
difference in the amount of IL-2 produced in the lung extracts of
IFN-
/
mice versus those of immunocompetent mice. The
data indicate that the lack of IFN-
switches cytokine responses to a
Th2 cytokine profile at the site of infection. Furthermore, either Th1-
or Th2-type cytokine responses in the lungs can provide heterosubtypic protection, since immunocompetent mice with a dominant Th1-type cytokine response and IFN-
/
mice with a dominant
Th2-type cytokine response developed complete recovery from challenge
with a lethal dose of influenza virus.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 4.
Th1- and Th2-type cytokine production in lung extracts.
BALB/c IFN- / and WT mice were immunized with
influenza virus A/Udorn (H3N2) by different routes, as indicated. Four
weeks later, the mice were challenged with the heterologous
mouse-adapted A/PR/8/34 (H1N1) influenza virus via the TRT route. On
day 3 after challenge, mice were sacrificed, and lung extracts were
collected and assayed for the level of cytokines as determined by
ELISA. The values represent the mean and SEM of the amount of cytokines
for five mice in each group.
|
|
Induction of humoral immune responses to influenza virus in
IFN-
/
mice.
VN activity is required for
Ab-mediated protection, while nonneutralizing Abs, which bind to
virus-infected cells, can reduce the production of progeny virus
(24). Thus, Abs could have a potential role as mediators of
HSI. IFN-
has been reported to be crucial in Ab class switching
during maturation of humoral immune responses (5, 35). The
impact of IFN-
on induction of VN and serotype cross-reactive Abs
was studied in our system. Immunocompetent and IFN-
/
mice were immunized by the i.v. or TRT routes with live A/Udorn virus.
One month later, sera from immunized mice were assayed for the presence
of VN and anti-NP Abs. Both immunocompetent and IFN-
/
mice displayed significant and comparable
titers of VN Abs specific for the immunizing but not the challenge
virus (Table 1) (one-way analysis of
variance with a P value of <0.0001). This was true for sera
collected 3 days after the challenge with heterologous influenza virus
(data not shown). This result supports the observations described
above, where IFN-
/
mice immunized with a homologous
virus serotype were protected from challenge with a lethal dose of
influenza virus. The protection of these mice from secondary infection
is presumably mediated by VN Abs induced by primary infection. The
results clearly demonstrate that lack of IFN-
does not impair the
induction of neutralizing Abs. However, the titers of VN Abs specific
for immunizing virus did not correlate with protection against
challenge with a lethal dose of heterologous influenza virus.
Lack of IFN-

did not impair induction of anti-NP Abs. No
statistically significant difference in serum anti-NP Ab titers
was
found between IFN-

/
and immunocompetent mice (Table
1). The level of Abs measured
before the challenge did not differ from
that detected 3 days
after the challenge (data not shown). No
statistically significant
difference in serum anti-NP Ab titers was
found between groups
of immunized mice. Also, no statistically
significant difference
in titers of subtype cross-reactive serum Ab, as
determined by
ELISA with whole virus subtypes as antigens, was found
between
groups of immunized mice (data not shown). The results confirm
previous results reported by our group (
25). Thus, no
correlation
between anti-NP- or subtype-specific serum Ab titers and
HSI was
observed. In IFN-

/
mice, an Ab class switch
to IgG1 was observed. Anti-NP IgG1/IgG2a
Ab ratios in
IFN-

/
mice were significantly higher than the ratios
determined in
WT mice (Fig.
5), although
the levels of anti-NP IgG2a were not
significantly lower than those of
normal mice (data not shown).
No significant differences were found
between ratios determined
before and after challenge of each group of
mice (Fig.
5). Thus,
our results most likely reflect a dominant
Th2-type cytokine response
in IFN-

/
mice.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 5.
Ratios of serum anti-NP IgG1 and IgG2a Abs in BALB/c
IFN- / and WT mice. Mice were immunized with
influenza virus A/Udorn (H3N2) by TRT. Four weeks later, the mice were
challenged with the heterologous mouse-adapted A/PR/8/34 (H1N1)
influenza virus. Sera were collected before and 3 days after challenge
and assayed for levels of anti-NP IgG1 and IgG2a Abs as determined by
ELISA. The values represent the ratios of the mean and SEM of antibody
titers for five mice in each group.
|
|
 |
DISCUSSION |
In this study, the importance of IFN-
in HSI to lethal
influenza infection was explored using a model of
IFN-
/
mice. Several important conclusions can be
drawn from this study: (i) IFN-
is not required for HSI to lethal
influenza virus infection, since HSI was observed in both
immunocompetent and IFN-
/
mice; (ii)
IFN-
-independent induction of virus-specific CTL responses induced
in MALT was associated with HSI; (iii) Ab responses measured by titers
of VN Ab and cross-reactive Abs to influenza A NP were not impaired in
IFN-
/
mice; and (iv) in the absence of IFN-
,
Th2-type cytokines were upregulated in the lungs upon challenge.
However, either Th1- or Th2-biased responses can be associated with
heterosubtypic protection.
Recovery from primary virus infection involves both innate and acquired
immunity. The latter is the major component of HSI, since it requires
previous immunization. Memory T cells are a major source of IFN-
in
heterosubtypically immune mice. HSI to lethal influenza virus infection
in the absence of IFN-
indicates that T cells function in HSI by
direct lysis of virus-infected cells or by secretion of alternative
compensatory antiviral cytokines other than IFN-
. Although IFN-
plays a protective role against infections for a number of
intracellular bacteria (2, 12) and viruses (11, 12, 15,
16, 19, 32, 43), it is not necessary for recovery from primary
infection with influenza virus (7). Therefore, it was
suggested that the importance of IFN-
in clearance of a viral
pathogen and recovery from infection depends upon the particular
microorganisms. This notion is supported by our findings. On the other
hand, the correlation between the level of IFN-
and HSI observed in
immunocompetent mice suggests a contribution of IFN-
to a complex
process involving possibly redundant host immune mechanisms. The
contribution of IFN-
may be substituted by other cytokines in the
absence of IFN-
. For example, TNF-
is known to participate in
recovery from hepatitis B virus infection (10). The role of
TNF-
for HSI in influenza virus infection is currently under
investigation by our group.
Differentiation of precursor CTL to activated CTL effectors is
dependent on IFN-
(21, 31); however, our results show that IFN-
is not required for activation of memory CD8+
CTL. The differentiation of memory precursors to activated CTL effectors occurs in the absence of IFN-
, since subtype-specific CD8+ CTL responses were induced in immunocompetent as well
as in IFN-
/
mice. In addition, when CTL precursors
were isolated from these mice, they differentiated into CTL effector
cells during in vitro stimulation in the absence of IFN-
. Previous
studies have shown that IFN-
is not required for induction of
effective CTL responses after primary virus infection (7).
Thus, IFN-
does not appear to be necessary for either the in vivo or
in vitro differentiation and effector function of CD8+ CTL.
Several host cytokines, including IL-2, IL-12, IFN-
, and TNF-
,
contribute to antiviral activity (for a review, see reference 27). While IFN-
and TNF-
contribute to direct
antiviral effects, IL-2 and IL-12 activate the host defense through
induction of CTL and NK cells. Although the level of IL-12 was not
measured in our study, unimpaired production of IL-2 in
IFN-
/
mice indicates that IL-2 may be an important
factor for induction of cellular immune responses in these mice. In
addition, increased levels of IL-4 observed in IFN-
/
mice suggests that IL-4 should be taken in account for the
IFN-
-independent pathway of induction and differentiation of
subtype-specific CD8+ CTL, since IL-4 is able to prime CTL
(37, 40).
The association between antigen-specific CD8+ CTL responses
in MLN and HSI in IFN-
/
mice suggests that these CTL
may play an important role in HSI to infection with influenza virus.
Since CTL have been shown to secrete IFN-
after antigenic
stimulation (22) and IFN-
is not involved in the host
recovery from lethal infection with a heterosubtypic strain of
cytopathic influenza virus, as shown in this study, it is likely that
direct lysis of infected cells by CD8+ T cells is the
dominant effector mechanism for virus clearance in HSI to influenza
virus infection. This is supported by previous findings in which
adoptive transfer of CTL clones generated from immunized
IFN-
/
mice to naive immunocompetent mice can promote
recovery from lethal viral challenge (7). Although the
systemic spread of the influenza virus strains was not analyzed in
detail, it is likely that the virus strains used would spread
systemically, since influenza-virus-specific Abs were detected in serum
after systemic or mucosal immunization. However, immunization by TRT exposure was much more effective than i.v. immunization for induction of antigen-specific CD8+ CTL responses in MLN and HSI in
immunocompetent as well as IFN-
/
mice. These
findings suggest that mucosal immunization preferentially induces
immune responses in MALT that are important for host defense against
mucosal pathogens, including influenza virus. Using C57BL/6 IFN-
/
mice, a recent study has shown that IFN-
played a protective role in HSI (1). In that system, the
immunization and challenge strategies were distinct from our protocol.
Immunocompetent as well as IFN-
/
mice were immunized
intraperitoneally and challenged via the aerosol route. Intraperitoneal
immunization is less effective in induction of HSI in immunocompetent
mice (25). TRT exposure to live virus has been the route of
choice for induction of HSI to influenza virus since the earliest
studies (3, 17, 25, 30, 46). Although immune responses were
in the BALB/c strain predominantly analyzed, HSI was already observed
in C57BL/6 IFN-
/
mice with a genetically distinct
background. These results indicate that the genetic background does not
affect IFN-
-independent induction of HSI.
Although IFN-
has potent effects on B-cell stimulation and antibody
secretion (5), there were no differences noted in the
induction of serum Ab responses to influenza virus between IFN-
/
and WT mice after infection, as measured by
serum VN as well as anti-NP Ab titers. Our results are in accord with
those obtained from the study of primary influenza virus infection
(7). In addition, the lack of IFN-
resulted in a switch
of cytokine production from Th1 to Th2 type, with significantly
enhanced IL-4 and IL-5 levels. This Th2-type cytokine switch is
normally associated with humoral immune responses (23).
Indeed, we observed an increased level of anti-NP IgG1 in
IFN-
/
mice (Fig. 5). This response was accompanied
by increased production of IL-4. Enhancement of Th2-type cytokine
production in IFN-
/
mice was also observed in
one study (7) but not in another (1). This
inconsistency may be the result of different protocols used for bulk
cultures on which cytokine analysis was performed. In our study, the
levels of cytokines in lung extracts were determined. This allows
better understanding of the regulation of immune responses at the site
of infection itself. Since serum titers of cross-reactive and anti-NP
Abs were not impaired in IFN-
/
mice and did not
correlate with host recovery from challenge, the role of
nonneutralizing Abs in the mucosal compartment (the site of influenza
virus infection) for HSI may be important and needs to be further
analyzed. In addition, although IFN-
/
mice are able
to develop functional HSI comparable with immunocompetent mice and it
is anticipated that long-term HSI may not be affected in
IFN-
/
mice, the long-term memory CD8+
CTL responses in MLN and HSI in IFN-
/
mice need to
be further explored. These points are currently under investigation in
our laboratory.
In summary, this study demonstrated that IFN-
is not required for
HSI to lethal influenza virus infection. Along with other available
knowledge, our findings suggest that HSI is a complex process which may
involve multiple biological factors. It is noteworthy that reduction of
virus replication in the lung varies from one study (17) to
another (3), and HSI mice exhibit only modest reductions in
lung virus titer (3). However, significant differences in
host morbidity and survival among these groups of mice suggest that
other factors controlling host resistance against virus infection, rather than virus clearance, may play an important role in HSI. In
addition, the question of how effective virus-specific CD8+
CTL responses are for protection needs to be further explored, since
adoptive transfer requires enormous numbers of in vitro-cloned virus-specific CD8+ CTL. On the other hand, it has been
reported recently that Abs specific for internal viral proteins
expressed on infected cells reduce the production of progeny virus and
inhibit the spread of infection in infected SCID mice (24).
The role of nonneutralizing Abs in MALT should be considered for HSI.
 |
ACKNOWLEDGMENTS |
We thank Michael W. Russell for critical reading and evaluation
of the manuscript.
This work was supported in part by U.S. PHS grants AI 28147, AI 43197, T32 AI 07150, and T32 HL 07553 and contract AI 65298.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, University of Alabama at Birmingham, Birmingham, AL
35294-2170. Phone: (205) 934-1737. Fax: (205) 934-3894. E-mail:
nghuan{at}uab.edu.
 |
REFERENCES |
| 1.
|
Bot, A.,
S. Bot, and C. A. Bona.
1998.
Protective role of gamma interferon during the recall response to influenza virus.
J. Virol.
72:6637-6645[Abstract/Free Full Text].
|
| 2.
|
Dalton, D.,
S. Pitts-Meek,
S. Keshav,
I. S. Figari,
A. Bradley, and T. A. Stewart.
1993.
Multiple defects of immune cell function in mice with disrupted interferon- genes.
Science
259:1739-1742[Abstract/Free Full Text].
|
| 3.
|
Epstein, S. L.,
C. Y. Lo,
J. A. Misplon,
C. M. Lawson,
B. A. Hendrickson,
E. E. Max, and K. Subbarao.
1997.
Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice.
J. Immunol.
158:1222-1230[Abstract].
|
| 4.
|
Fellous, M.,
U. Nir,
D. Wallach,
G. Merlin,
M. Rubinstein, and M. Revel.
1982.
Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells.
Proc. Natl. Acad. Sci. USA
79:3082-3086[Abstract/Free Full Text].
|
| 5.
|
Finkelman, F. D.,
I. M. Katona,
T. R. Mosmann, and R. L. Coffman.
1988.
IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses.
J. Immunol.
140:1022-1027[Abstract].
|
| 6.
|
Fu, T. M.,
L. Guan,
A. Friedman,
T. L. Schofield,
J. B. Ulmer,
M. A. Liu, and J. J. Donnelly.
1999.
Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.
J. Immunol.
162:4163-4170[Abstract/Free Full Text].
|
| 7.
|
Graham, M. B.,
D. K. Dalton,
D. Giltinan,
V. L. Braciale,
T. A. Stewart, and T. J. Braciale.
1993.
Response to influenza infection in mice with a targeted disruption in the interferon gamma gene.
J. Exp. Med.
178:1725-1732[Abstract/Free Full Text].
|
| 8.
|
Gray, P. W., and D. V. Goeddel.
1983.
Cloning and expression of murine immune interferon cDNA.
Proc. Natl. Acad. Sci. USA
80:5842-5846[Abstract/Free Full Text].
|
| 9.
|
Greenberger, M. J.,
R. M. Strieter,
S. L. Kunkel,
J. M. Danforth,
R. E. Goodman, and T. J. Standiford.
1995.
Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumoniae.
J. Immunol.
155:722-729[Abstract].
|
| 10.
|
Guidotti, L. G.,
T. Ishikawa,
M. V. Hobbs,
B. Matzke,
R. Schreiber, and F. V. Chisari.
1996.
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.
Immunity
4:25-36[CrossRef][Medline].
|
| 11.
|
Heise, M. T., and H. W. Virgin, IV.
1995.
The T-cell-independent role of gamma interferon and tumor necrosis factor alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infections.
J. Virol.
69:904-909[Abstract].
|
| 12.
|
Huang, S.,
W. Hendriks,
A. Althage,
S. Hemmi,
H. Bluethmann,
R. Kamijo,
J. Vilcek,
R. M. Zinkernagel, and M. Aguet.
1993.
Immune response in mice that lack the interferon-gamma receptor.
Science
259:1742-1745[Abstract/Free Full Text].
|
| 13.
|
Kagi, D., and H. Hengartner.
1996.
Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses.
Curr. Opin. Immunol.
8:472-477[CrossRef][Medline].
|
| 14.
|
Klein, J. R.,
D. H. Raulet,
M. S. Pasternack, and M. J. Bevan.
1982.
Cytotoxic T lymphocytes produce immune interferon in response to antigen or mitogen.
J. Exp. Med.
155:1198-1203[Abstract/Free Full Text].
|
| 15.
|
Kohonen-Corish, M. R.,
N. J. King,
C. E. Woodhams, and I. A. Ramshaw.
1990.
Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma.
Eur. J. Immunol.
20:157-161[Medline].
|
| 16.
|
Leist, T. P.,
M. Eppler, and R. M. Zinkernagel.
1989.
Enhanced virus replication and inhibition of lymphocytic choriomeningitis virus disease in anti-gamma interferon-treated mice.
J. Virol.
63:2813-2819[Abstract/Free Full Text].
|
| 17.
|
Liang, S.,
K. Mozdzanowska,
G. Palladino, and W. Gerhard.
1994.
Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity.
J. Immunol.
152:1653-1661[Abstract].
|
| 18.
|
Lin, Y. L., and B. A. Askonas.
1981.
Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions.
J. Exp. Med.
154:225-234[Abstract/Free Full Text].
|
| 19.
|
Lucchiari, M. A.,
M. Modolell,
K. Eichmann, and C. A. Pereira.
1992.
In vivo depletion of interferon-gamma leads to susceptibility of A/J mice to mouse hepatitis virus 3 infection.
Immunobiology
185:475-482[Medline].
|
| 20.
|
Lukacher, A. E.,
V. L. Braciale, and T. J. Braciale.
1984.
In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific.
J. Exp. Med.
160:814-826[Abstract/Free Full Text].
|
| 21.
|
Maraskovsky, E.,
W. F. Chen, and K. Shortman.
1989.
IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells.
J. Immunol.
143:1210-1214[Abstract].
|
| 22.
|
Morris, A. G.,
Y. L. Lin, and B. A. Askonas.
1982.
Immune interferon release when a cloned cytotoxic T-cell line meets its correct influenza-infected target cell.
Nature
295:150-152[CrossRef][Medline].
|
| 23.
|
Mosmann, T. R., and R. L. Coffman.
1989.
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.
Annu. Rev. Immunol.
7:145-173[CrossRef][Medline].
|
| 24.
|
Mozdzanowska, K.,
K. Maiese,
M. Furchner, and W. Gerhard.
1999.
Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection.
Virology
254:138-146[CrossRef][Medline].
|
| 25.
|
Nguyen, H. H.,
Z. Moldoveanu,
M. J. Novak,
F. W. van Ginkel,
E. Ban,
H. Kiyono,
J. R. McGhee, and J. Mestecky.
1999.
Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues.
Virology
254:50-60[CrossRef][Medline].
|
| 26.
|
Pestka, S.,
J. A. Langer,
K. C. Zoon, and C. E. Samuel.
1987.
Interferons and their actions.
Annu. Rev. Biochem.
56:727-777[CrossRef][Medline].
|
| 27.
|
Ramshaw, I. A.,
A. J. Ramsay,
G. Karupiah,
M. S. Rolph,
S. Mahalingam, and J. C. Ruby.
1997.
Cytokines and immunity to viral infections.
Immunol. Rev.
159:119-135[CrossRef][Medline].
|
| 28.
|
Restifo, N. P.,
F. Esquivel,
Y. Kawakami,
J. W. Yewdell,
J. J. Mule,
S. A. Rosenberg, and J. R. Bennink.
1993.
Identification of human cancers deficient in antigen processing.
J. Exp. Med.
177:265-272[Abstract/Free Full Text].
|
| 29.
|
Sarmiento, M.,
D. P. Dialynas,
D. W. Lancki,
K. A. Wall,
M. I. Lorber,
M. R. Loken, and F. W. Fitch.
1982.
Cloned T lymphocytes and monoclonal antibodies as probes for cell surface molecules active in T cell-mediated cytolysis.
Immunol. Rev.
68:135-169[CrossRef][Medline].
|
| 30.
|
Schulman, J. L., and E. D. Kilbourne.
1965.
Induction of partial specific heterotypic immunity in mice by a single infection with influenza virus.
J. Bacteriol.
89:170-174[Abstract/Free Full Text].
|
| 31.
|
Simon, M. M.,
U. Hochgeschwender,
U. Brugger, and S. Landolfo.
1986.
Monoclonal antibodies to interferon-gamma inhibit interleukin 2-dependent induction of growth and maturation in lectin/antigen-reactive cytolytic T lymphocyte precursors.
J. Immunol.
136:2755-2762[Abstract].
|
| 32.
|
Stanton, G. J.,
C. Jordan,
A. Hart,
H. Heard,
M. P. Langford, and S. Baron.
1987.
Nondetectable levels of interferon gamma is a critical host defense during the first day of herpes simplex virus infection.
Microb. Pathog.
3:179-183[CrossRef][Medline].
|
| 33.
|
Taylor, P. M., and B. A. Askonas.
1986.
Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo.
Immunology
58:417-420[Medline].
|
| 34.
|
Taylor, P. M.,
J. Davey,
K. Howland,
J. B. Rothbard, and B. A. Askonas.
1987.
Class I MHC molecules rather than other mouse genes dictate influenza epitope recognition by cytotoxic T cells.
Immunogenetics
26:267-272[CrossRef][Medline].
|
| 35.
|
Teale, J. M., and D. M. Estes.
1990.
Immunoglobulin isotype regulation, p. 173.
In
R. E. Callard (ed.), Cytokines and B lymphocytes. Academic Press, Inc., San Diego, Calif.
|
| 36.
|
Townsend, A. R. M.,
A. J. McMichael,
N. P. Carter,
J. A. Huddleston, and G. G. Brownlee.
1984.
Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells.
Cell
9:13-25.
|
| 37.
|
Trenn, G.,
H. Takayama,
J. Hu-Li,
W. E. Paul, and M. V. Sitkovsky.
1988.
B cell stimulatory factor 1 (IL-4) enhances the development of cytotoxic T cells from Lyt-2+ resting murine T lymphocytes.
J. Immunol.
140:1101-1106[Abstract].
|
| 38.
|
van Ginkel, F. W.,
J. R. McGhee,
C. Liu,
J. W. Simecka,
M. Yamamoto,
R. A. Frizzell,
E. J. Sorscher,
H. Kiyono, and D. W. Pascual.
1997.
Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene.
J. Immunol.
159:685-693[Abstract].
|
| 39.
|
Wells, M. A.,
S. Daniel,
J. Y. Djeu,
S. C. Kiley, and F. A. Ennis.
1983.
Recovery from a viral respiratory tract infection. IV. Specificity of protection by cytotoxic T lymphocytes.
J. Immunol.
130:2908-2914[Abstract].
|
| 40.
|
Widmer, M. B., and K. H. Grabstein.
1987.
Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor.
Nature
326:795-798[CrossRef][Medline].
|
| 41.
|
Wraith, D. C.,
A. E. Vessey, and B. A. Askonas.
1987.
Purified influenza virus nucleoprotein protects mice from lethal infection.
J. Gen. Virol.
68:433-440[Abstract/Free Full Text].
|
| 42.
|
Yang, Y.,
J. B. Waters,
K. Fruh, and P. A. Peterson.
1992.
Proteasomes are regulated by interferon gamma: implications for antigen processing.
Proc. Natl. Acad. Sci. USA
89:4928-4932[Abstract/Free Full Text].
|
| 43.
|
Yang, Y.,
Z. Xiang,
H. C. Ertl, and J. M. Wilson.
1995.
Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo.
Proc. Natl. Acad. Sci. USA
92:7257-7261[Abstract/Free Full Text].
|
| 44.
|
Yap, K. L., and G. L. Ada.
1978.
The recovery of mice from influenza virus infection: adoptive transfer of immunity with immune T lymphocytes.
Scand. J. Immunol.
7:389-397[CrossRef][Medline].
|
| 45.
|
Yap, K. L.,
G. L. Ada, and I. F. McKenzie.
1978.
Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus.
Nature
273:238-239[CrossRef][Medline].
|
| 46.
|
Yetter, R. A.,
S. Lehrer,
R. Ramphal, and P. A. J. Small.
1980.
Outcome of influenza infection: effect of site of initial infection and heterotypic immunity.
Infect. Immun.
29:654-662[Abstract/Free Full Text].
|
| 47.
|
Yewdell, J. W.,
J. R. Bennink,
G. L. Smith, and B. Moss.
1985.
Influenza virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes.
Proc. Natl. Acad. Sci. USA
82:1785-1789[Abstract/Free Full Text].
|
Journal of Virology, June 2000, p. 5495-5501, Vol. 74, No. 12
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Quan, F.-S., Compans, R. W., Nguyen, H. H., Kang, S.-M.
(2008). Induction of Heterosubtypic Immunity to Influenza Virus by Intranasal Immunization. J. Virol.
82: 1350-1359
[Abstract]
[Full Text]
-
Woodberry, T., Gardner, J., Elliott, S. L., Leyrer, S., Purdie, D. M., Chaplin, P., Suhrbier, A.
(2003). Prime Boost Vaccination Strategies: CD8 T Cell Numbers, Protection, and Th1 Bias. J. Immunol.
170: 2599-2604
[Abstract]
[Full Text]
-
Guy, B.
(2002). Evaluation of Events Occurring at Mucosal Surfaces: Techniques Used To Collect and Analyze Mucosal Secretions and Cells. CVI
9: 753-762
[Full Text]
-
Tsunetsugu-Yokota, Y., Tamura, H., Tachibana, M., Ogata, K., Honda, M., Takemori, T.
(2002). Selective expansion of perforin-positive CD8+ T cells by immature dendritic cells infected with live Bacillus Calmette-Guerin mycobacteria. J. Leukoc. Biol.
72: 115-124
[Abstract]
[Full Text]
-
Tumpey, T. M., Renshaw, M., Clements, J. D., Katz, J. M.
(2001). Mucosal Delivery of Inactivated Influenza Vaccine Induces B-Cell-Dependent Heterosubtypic Cross-Protection against Lethal Influenza A H5N1 Virus Infection. J. Virol.
75: 5141-5150
[Abstract]
[Full Text]